William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.
Terns Pharmaceuticals halts development of oral GLP-1 obesity treatment TERN-601 after Phase 2 trial shows modest weight loss and liver safety concerns.
Truist initiates Terns Pharmaceuticals with Buy rating and $20 target, citing promising blood cancer drug and oral GLP-1 treatment potential.
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
